Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential

Thrombosis and Haemostasis

Volumn 87, Issue 4, 2002, Pages 606-613

  Chan, Anthony K C ^a   Berry, Leslie R ^a   Monagle, Paul T ^a   Andrew, Maureen ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Anticoagulant; Heparin; Newborn; Plasma; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; CHROMOGENIC SUBSTRATE; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN; THROMBIN ALPHA 2 MACROGLOBULIN INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCIFICATION; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FRACTIONATION; HUMAN; INHIBITION KINETICS; MOLECULAR WEIGHT; NEWBORN; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOEMBOLISM; UMBILICAL CORD;

EID: 0036215406     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613056     Document Type: Article

References (49)

1. The prevention and treatment of thromboembolic disease in children: A need for thrombophilia programs
2. 1-800-NO-CLOTS: A quaternary care solution to a new tertiary care disease: Childhood thrombophilia
3. The use of low molecular weight heparin in pediatric patients: A prospective cohort study
4. Antithrombotic therapy in children
5. Benefit of heparin in peripheral venous and arterial catheters: Systematic review and meta-analysis of randomized controlled trials
6. Guidelines for antithrombotic therapy in pediatric patients
7. Childhood thrombophilia programs: An approach to the prevention and treatment of thromboembolic disease in pediatric patients
8. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients
9. Oral anticoagulation therapy in children
10. Outcome of pediatric thromboembolic disease: A report from the Canadian Childhood Thrombophilia Registry
11. Maturation of the hemostatic system during childhood
12. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass
13. Disorders of hemostasis in childhood: Risk factors for venous thromboembolism
14. Diagnosis and treatment of venous thromboembolism in children and adolescents. On behalf of the Subcommittee on Perinatal Haemostasis of the Scientific and Standardization Committee of the ISTH
15. Alpha-2-macroglobulin remains as important as antithrombin III for thrombin regulation in cord plasma in the presence of endothelial cell surfaces
16. Thrombin regulation in children differs from adults in the absence and presence of heparin
17. Development of the human coagulation system in the healthy premature infant
18. Development of the human coagulation system in the full-term infant
19. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin
20. Alpha-2-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma
21. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III deficient children
22. Microtechnology for the study of the blood coagulation system in newborn infants
23. Anticoagulant effects of heparin in neonatal plasma
24. A549 lung epithelial cell line synthesize anticoagulant molecules on the cell surface, matrix, and in conditioned media
25. Covalent antithrombin-heparin complexes with high anticoagulant activity: Intravenous, subcutaneous and intratracheal administration
26. Overview of hemostasis
27. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin
28. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa
29. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin
30. The molecular structure of fibrinogen
31. Platelet activation by α-thrombin is a receptor-mediated event
32. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: Methods and clinical applications
33. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation
34. Phospholipase A2: Its role in ADP- and thrombin-induced platelet activation mechanisms
35. Active site-blocked activated factor VII as an effective antithrombotic agent: Mechanism of action
36. Observation on the prophylactic use of vitamin K in the newborn
37. Thrombin activates factor XI on activated platelets in the absence of factor XII
38. Heparin sensitivity and resistance in the neonate: An explanation
39. Thrombin inhibition is impaired in plasma of sick neonates
40. Involvement of heparin chain length in the heparin catalyzed inhibition of thrombin by antithrombin III
41. Enhanced thrombin regulation during warfarin therapy in children compared to adults
42. Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex
43. Spontaneous arterial thrombosis in children
44. Neonatal thrombotic disease: Prevention, diagnosis and therapy
45. Alpha-2-macroglobulin remains as important as ATIII for thrombin regulation in cord plasma in the presence of endothelial cell surfaces
46. Thrombin inhibition by fetal distal lung epithelium is different in fetal and adult plasma
47. Low molecular weight heparins
48. Low molecular weight heparins: Treatment of venous thromboembolism
49. Biochemical and pharmacological profile of low molecular weight heparin (LU 47311, Clivarin)